Related Experiment Video
Updated: Jun 25, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge?
Ellen G Neven1, Marc E De Broe, Patrick C D'Haese
1Department of Pathophysiology, University of Antwerp, Antwerp, Belgium.
Abstract:
Arterial calcification has been found to coexist with bone loss. Bisphosphonates, used as standard therapy for osteoporosis, inhibit experimentally induced vascular calcification, offering perspectives for the treatment of vascular calcification in renal failure patients. However, Lomashvili et al. report that the doses of etidronate and pamidronate that are effective in attenuating aortic calcification also decrease bone formation and mineralization in uremic rats, limiting their therapeutic use as anticalcifying agents.
Insights
Bisphosphonates may treat arterial calcification in kidney disease. However, effective doses also harm bone formation in rats, limiting their use as anticalcifying agents for osteoporosis and vascular calcification.
Area of Science:
- Biochemistry
- Nephrology
- Orthopedics
Background:
- Arterial calcification frequently co-occurs with bone loss.
- Bisphosphonates are standard osteoporosis treatments.
- Bisphosphonates show potential for treating vascular calcification, especially in renal failure.
Purpose of the Study:
- To investigate the dual effects of bisphosphonates on bone and vascular calcification.
- To assess the therapeutic potential of bisphosphonates as anticalcifying agents in renal failure.
Main Methods:
- Uremic rat models were used.
- Administration of etidronate and pamidronate at doses effective against aortic calcification.
Main Results:
- Effective doses of etidronate and pamidronate significantly decreased bone formation.
- These doses also impaired bone mineralization in uremic rats.
- The study highlights a limitation in using bisphosphonates for vascular calcification due to bone side effects.
Conclusions:
- While bisphosphonates can inhibit vascular calcification, their detrimental effects on bone formation and mineralization limit their therapeutic application.
- Further research is needed to develop safer anticalcifying agents for patients with coexisting bone and vascular conditions.
Related Concept Videos
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Bone Remodeling
